Characterizing the antibody response to amustaline/glutathione pathogen-reduced red blood cells.

Background: The clinical significance of natural and treatment-emergent antibodies specific for amustaline/glutathione pathogen-reduced red blood cells (PRRBCs) is not known.

Study Design And Methods: A Phase 3, randomized clinical trial of PRRBCs (ReCePI) compared PRRBCs with conventional RBCs in cardiac or thoracic-aorta surgery. Subjects transfused during and for 7 days after surgery were screened for PRRBC-specific antibodies at baseline, 28 and 75 days post-surgery.

Analysis of patient-specific factors contributing to effectiveness of glucagon-like peptide-1 receptor agonists.

Background: Glucagon-like peptide-1 receptor (GLP-1) agonists are antidiabetic medications used to improve hemoglobin A1c (HbA1c) and promote weight loss. Per the Veterans Affairs/Department of Defense guidelines for the management of type 2 diabetes, GLP-1 agonists are expected to lower HbA1c by 1%-1.5%.